Research summary, original research, 2011

Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD-Matrix Trial

Sciahbasi A, Frigoli E, Sarandrea A, Rothenbühler M, Calabrò P, Lupi A, et al.. Journal of the American College of Cardiology. 2011

Read the original paper

In plain language

In a randomized trial of coronary procedures, radial access gave interventional cardiologists roughly twice the thorax radiation dose of femoral access, and patients slightly more fluoroscopy time and dose-area product (DAP). Wrist and head doses did not differ.

At a glance

Type of study
Original research, Randomized trial
Who was studied
Interventional cardiologists, Patients
Size
n = 777 procedures
Summary based on
the abstract

What it found

  • Operator thorax dose was higher with radial than femoral access, and noninferiority of radial access was not shown.

    Key figures: 77 μSv vs 41 μSv; p = 0.02; p for noninferiority = 0.843

  • The difference in operator dose persisted after normalizing for fluoroscopy time or DAP.

  • In the full MATRIX population, fluoroscopy time and DAP were higher with radial access.

    Key figures: 10 min vs 9 min (p < 0.0001); 65 Gy·cm2 vs 59 Gy·cm2 (p = 0.0001)

  • Wrist and head doses did not differ between radial and femoral access.

  • Thorax operator dose did not differ significantly between right and left radial access.

    Key figures: 84 μSv vs 52 μSv; p = 0.15

Limits to keep in mind

The radiation sub-study included only 18 expert operators and 777 procedures. Thorax dosimetry may not reflect dose under protective garments or to other team members, and the abstract does not report country or shielding details.

How this summary was made

ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.